Life science equipment specialist Lumicks has announced the closing of its series D investment round. This time around, the Amsterdam-based startup added 93 million dollars (77 million euros) to its coffers. According to Lumicks, the majority of these funds are earmarked to help support the company’s growth initiatives, including the expansion of its R&D and commercial activities for its next-gen platforms for dynamic single-molecule and cell avidity analysis – the Z-movi.
The Z-movi analyzer platform rapidly measures the binding strength between target and immune cells, providing high-throughput results with single-cell resolution. The data are key metrics that correlate with the biological outcome of cellular immunotherapies. Cell avidity insights provide researchers with reproducible and predictive information about the best therapeutic candidates at an early stage, potentially leading to improved candidate selection and dramatically faster drug development. Since its release in 2020, the Z-movi has been adopted by leading biotech and pharmaceutical companies around the world to accelerate the entry of cell therapies into clinical trials.
The funding round was led by new investors Farallon Capital Management and Lauxera Capital Partners and included investments by Softbank Vision 2, funds and accounts advised by T. Rowe Price Associates, Parian Global Management, Pura Vida Investments and Irving Investors. The round was also backed by existing investor Gilde Healthcare and select members of the Lumicks management team.
This article is exclusively available to premium members of Bits&Chips. Already a premium member? Please log in. Not yet a premium member? Become one for just €20 for the first year and enjoy all the benefits.
